FDA’s Oncologic Drugs Advisory Cmte. Will Review Avastin In Breast Cancer Dec. 5
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC will address Genentech’s sBLA for bevacizumab in combination with paclitaxel for patients who have not received chemotherapy for locally recurrent or metastatic HER2 negative breast cancer.